Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity

Protein Science

Volumn 15, Issue 5, 2006, Pages 987-999

  De Jésus Tran, Karine Pereira ^a   Côté, Pierre Luc ^a   Cantin, Line ^a   Blanchet, Jonathan ^a,b   Labrie, Fernand ^a   Breton, Rock ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Agonists; Crystal structure; Human androgen receptor; Ligand binding pocket; Tetrahydrogestrinone

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; LIGAND; METRIBOLONE; TESTOSTERONE; TETRAHYDROGESTRINONE;

AGONIST; ARTICLE; BINDING AFFINITY; CHEMICAL BOND; CHEMICAL MODIFICATION; CRYSTAL STRUCTURE; DOPING; GEOMETRY; HORMONE DETERMINATION; HORMONE RECEPTOR INTERACTION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; STRUCTURE ANALYSIS;

ANDROGEN ANTAGONISTS; BINDING SITES; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DIHYDROTESTOSTERONE; GESTRINONE; HUMANS; HYDROGEN BONDING; LIGANDS; MOLECULAR STRUCTURE; MULTIPROTEIN COMPLEXES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; TESTOSTERONE;

EID: 33646138016     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.051905906     Document Type: Article

References (59)

1. Blanchet, J., Lin, S.-X., and Zhorov, B.S. 2005. Mapping of steroids binding to 17β-hydroxysteroid dehydrogenase type 1 using Monte Carlo energy minimization reveals alternative binding modes. Biochemistry 44: 7218-7227.
2. Bohl, C.E., Gao, W., Miller, D.D., Bell, C.E., and Dalton, J.T. 2005a. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. 102: 6201-6206.
3. Bohl, C.E., Miller, D.D., Chen, J., Bell, C.E., and Dalton, J.T. 2005b. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J. Biol. Chem. 280: 37747-37754.
4. Brünger, A.T. 1992. The free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 355: 472-474.
5. Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. 1998. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54: 905-921.
6. Catlin, D.H., Sekera, M.H., Ahrens, B.D., Starcevic, B., Chang, Y.C., and Hatton, C.K. 2004. Tetrahydrogestrinone: Discovery, synthesis, and detection in urine. Rapid Commun. Mass Spectrom. 18: 1245-1249.
7. Chavez, B., Mendez, J.P., Ulloa-Aguirre, A., Larrea, F., and Vilchis, F. 2001. Eight novel mutations of the androgen receptor gene in patients with androgen insensitivity syndrome. J. Hum. Genet. 46: 560-565.
8. CCP4 (Collaborative Computational Project, Number 4)1994. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50: 760-763.
9. Dawood, M.Y., Obasiolu, C.W., Ramos, J., and Khan-Dawood, F.S. 1997. Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am. J. Obstet. Gynecol. 176: 387-394.
10. Death, A.K., McGrath, K.C., Kazlauskas, R., and Handelsman, D.J. 2004. Tetrahydrogestrinone is a potent androgen and progestin. J. Clin. Endocrinol. Metab. 89: 2498-2500.
11. De Bellis, A., Quigley, C.A., Cariello, N.F., El-Awady, M.K., Sar, M., Lane, M.V., Wilson, E.M., and French, F.S. 1992. Single base mutations in the androgen receptor gene causing complete androgen insensitivity: Rapid detection by a modified denaturing gradient gel electrophoresis technique. Mol. Endocrinol. 6: 1909-1920.
12. Dewar, M.J.S., Zoebisch, E.G., Healy, E.F., and Stewart, J.J.P. 1985. AM1: A new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107: 3902-3909.
13. Espinosa, E., Molins, E., and Lecomte, C. 1998. Hydrogen bond strengths revealed by topological analyses of experimentally observed electron densities. Chem. Phys. Lett. 285: 170-173.
14. Estebanez-Perpina, E., Moore, J.M., Mar, E., Delgado-Rodrigues, E., Nguyen, P., Baxter, J.D., Buehrer, B.M., Webb, P., Fletterick, R.J., and Guy, R.K. 2005. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J. Biol. Chem. 280: 8060-8068.
15. Evans, N.A. 2004. Current concepts in anabolic-androgenic steroids. Am. J. Sports Med. 32: 534-542.
16. Gaddipati, J.P., McLeod, D.G., Heidenberg, H.B., Sesterhenn, I.A., Finger, M.J., Moul, J.W., and Srivastava, S. 1994. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54: 2861-2864.
17. Gronemeyer, H., Gustafsson, J.A., and Laudet, V. 2004. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3: 950-964.
18. Harris, S.E., Rong, Z., Harris, M.A., and Lubahn, D.B. 1990. Androgen receptor in human prostate carcinoma LNCaP/ADEP cells contains a mutation which alters the specificity of the steroid-dependent transcriptional activation region (Abstract 275). In Program of the 72nd Annual Meeting of The Endocrine Society, Atlanta, GA.
19. Harris, S.E., Harris, M.A., Rong, Z., Hall, J., Judge, S., French, F.S., Joseph, D.R., Lubahn, D.B., Simental, J.A., and Wilson, E.M. 1991. Androgen regulation of HBGF-1 (aFGF) mRNA and characterization of the androgen-receptor mRNA in the human prostate carcinoma cell line - LNCaP/A-DEP. In Molecular and cellular biology of prostate cancer (eds. J.P. Karr et al.) pp. 315-330. Plenum Press, New York.
20. He, B., Gampe Jr., R.T., Kole, A.J., Hnat, A.T., Stanley, T.B., An, G., Stewart, E.L., Kalman, R.I., Minges, J.T., and Wilson, E.M. 2004. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol. Cell 16: 425-438.
21. Heinlein, C.A. and Chang, C. 2004. Androgen receptor in prostate cancer. Endocr. Rev. 25: 276-308.
22. Hur, E., Pfaff, S.J., Payne, E.S., Gron, H., Buehrer, B.M., and Fletterick, R.J. 2004. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol. 2: E274.
23. Jasuja, R., Catlin, D.H., Miller, A., Chang, Y.C., Herbst, K.L., Starcevic, B., Artaza, J.N., Singh, R., Datta, G., Sarkissian, A., et al. 2005. Tetrahydrogestrinone is an androgenic steroid that stimulates androgen receptor-mediated, myogenic differentiation in C3H10T1/2 multipotent mesenchymal cells and promotes muscle accretion in orchidectomized, male rats. Endocrinology 146: 4472-4478.
24. Jenster, G. 1998. Coactivators and corepressors as mediators of nuclear receptor function: An update. Mol. Cell. Endocrinol. 143: 1-7.
25. Jenster, G., van der Korput, H.A., van Vroonhoven, C., van der Kwast, T.H., Trapman, J., and Brinkmann, A.O. 1991. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. 5: 1396-1404.
26. Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. 1991. Improved methods for the building of protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47: 110-119.
27. Kabsch, W. 1993. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 26: 795-800.
28. Kaplan, W. and Littlejohn, T.G. 2001. Swiss-PDB Viewer (Deep View). Brief Bioinform. 2: 195-197.
29. Keller, E.T., Ershler, W.B., and Chang, C. 1996. The androgen receptor: A mediator of diverse responses. Front. Biosci. 1: d59-d71.
30. Kraulis, P.J. 1991. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24: 946-950.
31. Labrie, F., Candas, B., Gomez, J.L., and Cusan, L. 2002. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 60: 115-119.
32. Labrie, F., Luu-The, V., Calvo, E., Martel, C., Cloutier, J., Gauthier, S., Belleau, P., Morissette, J., Levesque, M.H., and Labrie, C. 2005. Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. J. Endocrinol. 184: 427-433.
33. Laskowski, R.A., MacArthur, M.W., Moss, D.S., and Thornton, J.M. 1993. PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26: 283.
34. Lazaridis, T. and Karplus, M. 1999. Effective energy function for proteins in solution. Proteins 35: 152-156.
35. Li, Z. and Scheraga, H.A. 1987. Monte Carlo-minimization approach to the multiple-minima problem in protein folding. Proc. Natl. Acad. Sci. 84: 6611-6615.
36. Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. 1995. The nuclear receptor superfamily: The second decade. Cell 83: 835-839.
37. Matias, P.M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. 2000. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275: 26164-26171.
38. Matias, P.M., Carrondo, M.A., Coelho, R., Thomaz, M., Zhao, X.Y., Wegg, A., Crusius, K., Egner, U., and Donner, P. 2002. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J. Med. Chem. 45: 1439-1446.
39. Mooradian, A.D., Morley, J.E., and Korenman, S.G. 1987. Biological actions of androgens. Endocr. Rev. 8: 1-28.
40. Mowszowicz, I., Riahi, M., Wright, F., Bouchard, P., Kuttenn, F., and Mauvais-Jarvis P. 1981. Androgen receptor in human skin cytosol. J. Clin. Endocrinol. Metab. 52: 338-344.
41. Murshudov, G.N., Vagin, A.A., and Dodson, E.J. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53: 240-255.
42. Navaza, J. 1994. AMoRe: An automated package for molecular replacement. Acta Crystallogr. A 50: 157-163.
43. Pinsky, L., Trifiro, M., Kaufman, M., Beitel, L.K., Mhatre, A., Kazemi-Esfarjani, P., Sabbaghian, N., Lumbroso, R., Alvarado, C., Vasiliou, M., et al. 1992. Androgen resistance due to mutation of the androgen receptor. Clin. Invest. Med. 15: 456-472.
44. Poujol, N., Wurtz, J.M., Tahiri, B., Lumbroso, S., Nicolas, J.C., Moras, D., and Sultan, C. 2000. Specific recognition of androgens by their nuclear receptor. A structure-function study. J. Biol. Chem. 275: 24022-24031.
45. Quigley, C.A., De Bellis, A., Marschke, K.B., el-Awady, M.K., Wilson, E.M., and French, F.S. 1995. Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocr. Rev. 16: 271-321.
46. Rao, C.N.R. 1972. Theory of hydrogen bonding in water. In Water: A comprehensive treatise (ed. F. Franks) Vol. 1, pp. 93-114. Plenum Press, New York.
47. Ris-Stalpers, C., Verleun-Mooijman, M.C., Trapman, J., and Brinkmann, A.O. 1993. Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity. Biochem. Biophys. Res. Commun. 196: 173-180.
48. Roy, A.K., Lavrovsky, Y., Song, C.S., Chen, S., Jung, M.H., Velu, N.K., Bi, B.Y., and Chatterjee, B. 1999. Regulation of androgen action. Vitam. Horm. 55: 309-352.
49. Sack, J.S., Kish, K.F., Wang, C., Attar, R.M., Kiefer, S.E., An, Y., Wu, G.Y., Scheffler, J.E., Salvati, M.E., Krystek Jr., S.R., et al. 2001. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. 98: 4904-4909.
50. Sakai, N., Yamada, T., Asao, T., Baba, M., Yoshida, M., and Murayama, T. 2000. Bilateral testicular tumors in androgen insensitivity syndrome. Int. J. Urol. 7: 390-392.
51. Taplin, M.E., Bubley, G.J., Shuster, T.D., Frantz, M.E., Spooner, A.E., Ogata, G.K., Keer, H.N., and Balk, S.P. 1995. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332: 1393-1398.
52. Veldscholte, J., Ris-Stalpen, C., Kuiper, G.G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H.C., Trapman, J., Brinkmann, A.O., and Mulder, E. 1990. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173: 534-540.
53. Wallace, A.C., Laskowski, R.A., and Thornton, J.M. 1995. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8: 127-134.
54. Weiner, S.J., Kollman, P.A., Case, D.A., Snigh, U.C., Ghio, C., Alagona, G., Profeta Jr., S., and Weiner, P. 1984. A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 106: 765-784.
55. Williams, S.P. and Sigler, P.B. 1998. Atomic structure of progesterone complexed with its receptor. Nature 393: 392-396.
56. Wurtz, J.M., Bourguet, W., Renaud, J.P., Vivat, V., Chambon, P., Moras, D., and Gronemeyer, H. 1996. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 3: 87-94.
57. Zhorov, B.S. 1983. Vector method for calculating derivatives of the energy deformation of valence angles and torsion energy of complex molecules according to generalized coordinates. J. Struct. Chem. 23: 649-655.
58. Zhorov, B.S. and Bregestovski, P.D. 2000. Chloride channels of glycine and GABA receptors with blockers: Monte Carlo minimization and structure-activity relationships. Biophys. J. 78: 1786-1803.
59. Zhorov, B.S. and Lin, S.-X. 2000. Monte Carlo-minimized energy profile of estradiol in the ligand-binding tunnel of 17β-hydroxysteroid dehydrogenase: Atomic mechanisms of steroid recognition. Proteins 38: 414-427.